MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot

Shares of Moderna (MRNA) declined nearly 8% yesterday after it announced that it had voluntarily withdrawn a regulatory filing seeking the FDA’s approval for mRNA-1083, its investigational mRNA-based combination vaccine against influenza and COVID. Per the company, the decision was taken in consultation with the agency.This announcement did not come as a surprise since MRNA had already announced earlier this month, alongside its Q1 results, that the FDA had requested ‘Phase 3 flu efficacy data.’ This setbac ...